In terms of route of administration, the global premature ejaculation market can be classified into two segments: oral therapies and topical therapies. In 2016, the global oral PE drugs segment accounted for a major share of 75.72% of the global PE market, according to the recent report, Premature Ejaculation Market – Global Outlook and Forecast 2017 – 2022 published by Arizton Advisory and Intelligence. The report published states that the topical PE market is expected to witness growth at a higher pace than the oral premature ejaculation market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period 2016–2022.

Oral administration refers to the route of administration where the drug is administered through the mouth. Oral therapies can be in the form of tablets, capsules, solutions, and suspensions. Currently, oral therapies for the PE market comprises tablets only.

Oral therapy is the most dominant segment of the global premature ejaculation market due to the presence of a wide range of drugs recommended by physicians for the management of the condition.

Topical medications refer to the drugs that are applied to the skin. Topical drug formulations include creams, gels, sprays, powders, emulsion, solutions, and ointments. Currently, creams, sprays, and gels are the common topical therapies.

Almost all the topical PE drug formulations are amide anesthetics, which comprise lidocaine, benzocaine or a combination of lidocaine and prilocaine. These formulations are available as OTC drugs, which can be purchased by the consumer without physicians’ prescription. This is the key factor, which boosts the product uptake of topical therapies in a vast majority of PE patients.

You may reach us at

Mail: enquiry@arizton.com

Call: +13124657864